Literature DB >> 26923637

miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.

Yuyan Han1, Fanyin Meng2, Julie Venter3, Nan Wu3, Ying Wan4, Holly Standeford5, Heather Francis2, Cynthia Meininger6, John Greene7, Jerome P Trzeciakowski6, Laurent Ehrlich3, Shannon Glaser8, Gianfranco Alpini9.   

Abstract

BACKGROUND & AIMS: Disruption of circadian rhythm is associated with cancer development and progression. MicroRNAs (miRNAs) are a class of small non-coding RNAs that trigger mRNA translation inhibition. We aimed to evaluate the role of Per1 and related miRNAs in cholangiocarcinoma growth.
METHODS: The expression of clock genes was evaluated in human cholangiocarcinoma tissue arrays and cholangiocarcinoma lines. The rhythmic expression of clock genes was evaluated in cholangiocarcinoma cells and H69 (non-malignant cholangiocytes) by qPCR. We measured cell proliferation, cell cycle and apoptosis in Mz-ChA-1 cells after Per1 overexpression. We examined tumor growth in vivo after injection of Per1 overexpressing cells. We verified miRNAs that targets Per1. The circadian rhythm of miR-34a was evaluated in cholangiocarcinoma and H69 cells. We evaluated cell proliferation, apoptosis and invasion after inhibition of miR-34a in vitro, and the potential molecular mechanisms by mRNA profiling after overexpression of Per1.
RESULTS: Expression of Per1 was decreased in cholangiocarcinoma. The circadian rhythm of Per1 expression was lost in cholangiocarcinoma cells. Decreased cell proliferation, lower G2/M arrest, and enhanced apoptosis were shown in Per1 overexpressing cells. An in vivo study revealed decreased tumor growth, decreased proliferation, angiogenesis and metastasis after overexpressing Per1. Per1 was verified as a target of miR-34a. miR-34a was rhythmically expressed in cholangiocarcinoma cells and H69. The inhibition of miR-34a decreased proliferation, migration and invasion in cholangiocarcinoma cells. mRNA profiling has shown that overexpression of Per1 inhibits cell growth through regulation of multiple cancer-related pathways, such as cell cycle, cell growth and apoptosis pathways.
CONCLUSIONS: Disruption of circadian rhythms of clock genes contribute to the malignant phenotypes of human cholangiocarcinoma. LAY
SUMMARY: The current study is about how biological clock and its regulators affect the bile duct tumor growth. The disruption of biological clock has a negative impact in different cancers. Per1 is a gene that is involved in maintaining the biological clock and show 24h oscillation. Reduced levels of Per1 and disruption of 24h circadian rhythm was found in bile duct cancer cells. Therefore, a genetic modified bile duct cancer cells was created. It has a higher level of Per1 expression and partially recovered circadian rhythm. Those genetic modified cells also displayed slower cell growth or higher rate of cell death. We also used mice model that lack of immune system to show that our genetic modified bile duct cells form smaller tumor. In addition, we tried to see how Per1 is communicating with other genes in regarding of controlling the tumor growth. We found Per1 is regulated by microRNA-34a, a small non-coding RNA that directly binds to genes and inhibit gene expression. Decreased level of miR-34a has also significantly reduced tumor growth through controlling the cell growth and cell death balance. Therefore bile duct cancer patients may be treated with miR-34a inhibitor or Per1 stimulator in the future. Published by Elsevier B.V.

Entities:  

Keywords:  Biliary epithelium; Cholangiocarcinoma; Circadian rhythm; Clock genes; microRNAs

Mesh:

Substances:

Year:  2016        PMID: 26923637      PMCID: PMC4874896          DOI: 10.1016/j.jhep.2016.02.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  43 in total

1.  Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells.

Authors:  Giles E Duffield; Jonathan D Best; Bernhard H Meurers; Anton Bittner; Jennifer J Loros; Jay C Dunlap
Journal:  Curr Biol       Date:  2002-04-02       Impact factor: 10.834

2.  Transcriptional regulation of the human Sp1 gene promoter by the specificity protein (Sp) family members nuclear factor Y (NF-Y) and E2F.

Authors:  Marta Nicolás; Vèronique Noé; Carlos J Ciudad
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

3.  Circadian transcription in liver.

Authors:  K Bozek; A L Rosahl; S Gaub; S Lorenzen; H Herzel
Journal:  Biosystems       Date:  2010-07-22       Impact factor: 1.973

4.  Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

Authors:  S Saijyo; T Kudo; M Suzuki; Y Katayose; M Shinoda; T Muto; K Fukuhara; T Suzuki; S Matsuno
Journal:  Tohoku J Exp Med       Date:  1995-09       Impact factor: 1.848

5.  SREBP-1 as a transcriptional integrator of circadian and nutritional cues in the liver.

Authors:  Michelle Brewer; David Lange; Ruben Baler; Ana Anzulovich
Journal:  J Biol Rhythms       Date:  2005-06       Impact factor: 3.182

Review 6.  Cholangiocarcinoma: increasing burden of classifications.

Authors:  Vincenzo Cardinale; Maria Consiglia Bragazzi; Guido Carpino; Alessia Torrice; Alice Fraveto; Raffaele Gentile; Vincenzo Pasqualino; Fabio Melandro; Camilla Aliberti; Carlo Bastianelli; Roberto Brunelli; Pasquale Bartolomeo Berloco; Eugenio Gaudio; Domenico Alvaro
Journal:  Hepatobiliary Surg Nutr       Date:  2013-10       Impact factor: 7.293

7.  MicroRNA-mediated regulation in the mammalian circadian rhythm.

Authors:  Kaihui Liu; Ruiqi Wang
Journal:  J Theor Biol       Date:  2012-04-08       Impact factor: 2.691

8.  A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium.

Authors:  M Miyagiwa; T Ichida; T Tokiwa; J Sato; H Sasaki
Journal:  In Vitro Cell Dev Biol       Date:  1989-06

9.  Biliary adenocarcinoma. Characterisation of three new human tumor cell lines.

Authors:  A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

10.  Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Authors:  Y Shimizu; A J Demetris; S M Gollin; P D Storto; H M Bedford; S Altarac; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

View more
  37 in total

1.  H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule.

Authors:  Yongfeng Song; Chune Liu; Xia Liu; Jocelyn Trottier; Michele Beaudoin; Li Zhang; Chad Pope; Guangyong Peng; Olivier Barbier; Xiaobo Zhong; Linheng Li; Li Wang
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

2.  Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.

Authors:  Indsey Kennedy; Heather Francis; Fanyin Meng; Shannon Glaser; Gianfranco Alpini
Journal:  Liver Res       Date:  2017-04-26

3.  Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡.

Authors:  Kelly McDaniel; Fanyin Meng; Nan Wu; Keisaku Sato; Julie Venter; Francesca Bernuzzi; Pietro Invernizzi; Tianhao Zhou; Konstantina Kyritsi; Ying Wan; Qiaobing Huang; Paolo Onori; Heather Francis; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Hepatology       Date:  2016-11-05       Impact factor: 17.425

4.  Upregulated lncRNA-UCA1 contributes to metastasis of bile duct carcinoma through regulation of miR-122/CLIC1 and activation of the ERK/MAPK signaling pathway.

Authors:  Lei Kong; Qinghua Wu; Liangchao Zhao; Jinhua Ye; Nengping Li; Huali Yang
Journal:  Cell Cycle       Date:  2019-05-20       Impact factor: 4.534

5.  Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.

Authors:  Chad Hall; Laurent Ehrlich; Julie Venter; April O'Brien; Tori White; Tianhao Zhou; Tien Dang; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Cancer Lett       Date:  2016-11-26       Impact factor: 8.679

6.  The let-7/Lin28 axis regulates activation of hepatic stellate cells in alcoholic liver injury.

Authors:  Kelly McDaniel; Li Huang; Keisaku Sato; Nan Wu; Tami Annable; Tianhao Zhou; Sugeily Ramos-Lorenzo; Ying Wan; Qiaobing Huang; Heather Francis; Shannon Glaser; Hidekazu Tsukamoto; Gianfranco Alpini; Fanyin Meng
Journal:  J Biol Chem       Date:  2017-05-23       Impact factor: 5.157

7.  MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.

Authors:  Gábor Lendvai; Tímea Szekerczés; Benedek Gyöngyösi; Krisztina Schlachter; Endre Kontsek; Adrián Pesti; Attila Patonai; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2018-11-09       Impact factor: 3.201

Review 8.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

9.  α7-nAChR Knockout Mice Decreases Biliary Hyperplasia and Liver Fibrosis in Cholestatic Bile Duct-Ligated Mice.

Authors:  Laurent Ehrlich; April O'Brien; Chad Hall; Tori White; Lixian Chen; Nan Wu; Julie Venter; Marinda Scrushy; Muhammad Mubarak; Fanyin Meng; David Dostal; Chaodong Wu; Terry C Lairmore; Gianfranco Alpini; Shannon Glaser
Journal:  Gene Expr       Date:  2018-03-26

Review 10.  Possible application of melatonin treatment in human diseases of the biliary tract.

Authors:  Leonardo Baiocchi; Tianhao Zhou; Suthat Liangpunsakul; Lenci Ilaria; Martina Milana; Fanyin Meng; Lindsey Kennedy; Praveen Kusumanchi; Zhihong Yang; Ludovica Ceci; Shannon Glaser; Heather Francis; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-11       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.